Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Two Medical Sciences researchers are amongst the seven successful applicants to have been chosen as the 2019-20 cohort of Public Engagement with Research (PER) Leaders.

Dr Katharine Owen (OCDEM, Radcliffe Department of Medicine) and Dr Sean Elias (Jenner InstituteNuffield Department of Medicine) are two of only seven researchers to be chosen in the 2019-20 cohort of Public Engagement with Research (PER) leaders at the University of Oxford. 

The PER Leadership scheme is for academics to take on a leadership role in a culture change project for their departments and faculties to enhance support for PER. The scheme is targeted at those who have a strong interest in PER, who want the opportunity to demonstrate their leadership skills within an academic environment and to explore new ways of working through facilitating change. The seven winners will each receive £5,000 to initiate PER-focused initiatives within their departments, and will participate in training from a variety of internal and external PER and leadership professionals throughout the coming year.

Dr Katharine Owen is a consultant endocrinologist and academic working in OCDEM (with an interest in rare monogenic forms of diabetes and young adult diabetes. She has organised events to showcase the research done at OCDEM and RDM, as well as to mark World Diabetes Day (pictured are schoolchildren recreating the 'blue ring' symbol for World Diabetes day around the Radcliffe Infirmary Fountain,  the 2018 event Dr Owen organised). Read more here.

Dr Sean Elias is Principal Investigator at the Jenner Institute studying non-typhoidal Salmonella (NTS). Since May 2016 he has been working with Professor Calman MacLennan on invasive NTS disease in Ghana and Burkina Faso and has more recently run his own clinical studies in the UK and Kenya looking at non-invasive sampling methods for gathering immunological data. As an immunologist he is interested in human antibody and cellular responses to NTS pathogens and how greater understanding of this can aid in future vaccine development. Since 2018 he has run his own public engagement initiative funded through the University Public Engagement with Research Seed Fund program: Oxford University Board Games & Public Engagement, which focuses on using board games to engage the public, using both commercial games and novel games designed by researchers at the University of Oxford.

 

Read more about the awards 

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.